Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...
The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...
News Medical on MSN3d
Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal cancerPatients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...
BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...
Pfizer has shared positive results from a late-stage study of its Braftovi (encorafenib) combination in BRAF V600E-mutant ...
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback